ReviewCirculation research2011
Derivation of human induced pluripotent stem cells for cardiovascular disease modeling.
Review in Circulation research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 70 citations in OpenAlex.
- A Hypoxia-reoxygenation Injury Model in Self-assembling Human Cardioids.Journal of visualized experiments : JoVE · 2026Article
- Quantifying HiPSC-CM structural organization at scale with deep learning-enhanced SarcGraph.PLoS computational biology · 2025Article
- Healthy human induced pluripotent stem cell-derived cardiomyocytes exhibit sex dimorphism even without the addition of hormones.Stem cells (Dayton, Ohio) · 2025Article
- Design considerations for engineering 3D models to study vascular pathologies in vitro.Acta biomaterialia · 2021Review
- Human iPSCs and Genome Editing Technologies for Precision Cardiovascular Tissue Engineering.Frontiers in cell and developmental biology · 2021Review
- Urine-Derived Induced Pluripotent Stem Cells in Cardiovascular Disease.Cardiology research and practice · 2020Review
- Gene Therapy Approaches to Biological Pacemakers.Journal of cardiovascular development and disease · 2018Review
- Manipulation-free cultures of human iPSC-derived cardiomyocytes offer a novel screening method for cardiotoxicity.Acta pharmacologica Sinica · 2018Article
- Modelling cadmium-induced cardiotoxicity using human pluripotent stem cell-derived cardiomyocytes.Journal of cellular and molecular medicine · 2018Article
- The march of pluripotent stem cells in cardiovascular regenerative medicine.Stem cell research & therapy · 2018Review
- Induced pluripotent stem cell: A headway in reprogramming with promising approach in regenerative biology.Veterinary world · 2017Review
- Computational cardiology and risk stratification for sudden cardiac death: one of the grand challenges for cardiology in the 21st century.The Journal of physiology · 2016Article
- Translation of Human-Induced Pluripotent Stem Cells: From Clinical Trial in a Dish to Precision Medicine.Journal of the American College of Cardiology · 2016Review
- Therapeutic Potential of Stem Cells Strategy for Cardiovascular Diseases.Stem cells international · 2016Review
- Genetic Variation, Not Cell Type of Origin, Underlies the Majority of Identifiable Regulatory Differences in iPSCs.PLoS genetics · 2016Article
- Perspectives of induced pluripotent stem cells for cardiovascular system regeneration.Experimental biology and medicine (Maywood, N.J.) · 2015Review
- Ion channelopathies in human induced pluripotent stem cell derived cardiomyocytes: a dynamic clamp study with virtual IK1.Frontiers in physiology · 2015Article
- Generation of Functional Cardiomyocytes from Efficiently Generated Human iPSCs and a Novel Method of Measuring Contractility.PloS one · 2015Article
- iPS cell-derived cardiogenicity is hindered by sustained integration of reprogramming transgenes.Circulation. Cardiovascular genetics · 2014Article
- Pluripotent Stem Cell Therapy in Ischemic Cardiovascular Disease.Acta Cardiologica Sinica · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The successful derivation of human induced pluripotent stem cells (hiPSCs) by dedifferentiation of somatic cells offers significant potential to overcome obstacles in the field of cardiovascular disease. hiPSC derivatives offer incredible potential for new disease models and regenerative medicine therapies. However, many questions remain regarding the optimal starting materials and methods to enable safe, efficient derivation of hiPSCs suitable for clinical applications. Initial reprogramming experiments were carried out using lentiviral or retroviral gene delivery methods. More recently, various nonviral methods that avoid permanent and random transgene insertion have emerged as alternatives. These include transient DNA transfection using plasmids or minicircles, protein transduction, or RNA transfection. In addition, several small molecules have been found to significantly augment hiPSC derivation efficiency, allowing the use of a fewer number of genes during pluripotency induction. We review these various methods for the derivation of hiPSCs, focusing on their ultimate clinical applicability, with an emphasis on their potential for use as cardiovascular therapies and disease-modeling platforms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.